Biostudies and biowaivers

DADA has supervised or monitored more than 100 complete BA/BE projects and has evaluated many more bioequivalence studies conducted by other companies. Thus, DADA has acquired a vast body of knowledge about this very specific subject. DADA has demonstrated that it is not only able to adequately monitor bioequivalence studies; it is also able to find creative solutions for non-standard problem situations.

Besides monitoring studies, DADA has also supported many companies when bioequivalence studies produced suboptimal or unexpected results. By creatively re-evaluating all available data, it was often possible to explain deviating test results and to provide satisfactory answers to questions raised by the regulatory authorities. This has resulted in a number of publications in peer-reviewed scientific literature, confirming the state-of-the-art quality of services rendered by DADA.

When bioequivalence studies fail to show equivalence of the test and reference drugs, DADA can review the study data and determine the reasons for non-equivalence. Based on their analysis, these experts can recommend further actions.

The Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **) provides criteria for when a drug or drug strength does not need to undergo a bioequivalence study. These requirements are extensive, and DADA has experts capable of evaluating your product and writing a biowaiver where applicable.

DADA experts can evaluate old bioequivalence study reports that may need to be resubmitted for regulatory review (e.g. for new applicants or additional countries). Our experts have prepared numerous justifications for lack of Incurred Sample Reanalysis (ISR). The requirement to perform ISR was introduced with the Guideline on bioanalytical method validation (EMEA/CHMP/EWP/192217/2009), which came into force on 1 February 2012.